Loading...
•
Dec 31, 2024
Bioventus Q4 2024 Earnings Report
Bioventus reported strong revenue growth and improved profitability in Q4 2024.
Key Takeaways
Bioventus achieved a 13.5% increase in revenue for Q4 2024, driven by double-digit growth in Pain Treatments and Surgical Solutions. The company posted an adjusted EBITDA of $28.3 million, up 28.3% year-over-year. Non-GAAP EPS rose to $0.15 from $0.07 in the prior year. Net loss from continuing operations significantly improved to $0.3 million compared to $7.7 million in Q4 2023.
Q4 revenue increased by 13.5% year-over-year to $153.6 million.
Adjusted EBITDA grew 28.3% to $28.3 million, reflecting higher profitability.
Non-GAAP EPS rose to $0.15 per share from $0.07 in the previous year.
Net loss from continuing operations significantly narrowed to $0.3 million.
Bioventus
Bioventus
Bioventus Revenue by Segment
Bioventus Revenue by Geographic Location
Revenue by Segment
Pain Treatments Revenue
CapyFin.comSurgical Solutions Revenue
CapyFin.comRestorative Therapies Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Bioventus expects full-year 2025 revenue of $560M to $570M, reflecting 6.1% to 8.0% organic growth, alongside a projected adjusted EBITDA margin expansion.
Positive Outlook
- Full-year 2025 revenue expected to reach $560M to $570M.
- Projected organic revenue growth of 6.1% to 8.0%.
- Adjusted EBITDA expected to grow to $112M - $116M.
- Non-GAAP EPS forecasted to increase by 30.6% to 38.8%.
- Ongoing operational improvements expected to enhance profitability.
Challenges Ahead
- Guidance excludes potential acquisitions and divestitures.
- Macroeconomic headwinds may impact overall growth.
- Increasing competition in pain treatment and surgical solutions.
- Potential regulatory changes could affect market positioning.
- Foreign exchange fluctuations may influence financial results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income